Inhibiting beta-catenin to treat porphyria
Beta-catenin inhibition as a novel therapeutic strategy for porphyria
This study is exploring a new treatment for porphyria that aims to help reduce symptoms and slow down the disease by targeting a specific pathway in the body, and it could offer a better option for patients looking for more than just temporary relief.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10890634 on NIH RePORTER |
What this research studies
This research investigates a new therapeutic approach for porphyria, a group of metabolic disorders caused by defects in heme biosynthesis. The study focuses on inhibiting the Wnt/beta-catenin signaling pathway, which has been shown to reduce liver injury and porphyrin accumulation in animal models. By understanding how beta-catenin affects key enzymes involved in heme production, the researchers aim to develop a treatment that could alleviate symptoms and slow disease progression. Patients may benefit from a novel therapy that targets the underlying mechanisms of their condition rather than just providing symptomatic relief.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute porphyria or related metabolic disorders.
Not a fit: Patients with chronic porphyrias or those who do not have a diagnosis related to heme biosynthesis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly improves the quality of life for patients with porphyria.
How similar studies have performed: Previous studies have shown promise in targeting the Wnt/beta-catenin pathway for therapeutic purposes, indicating potential for success in this approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Nejak-Bowen, Kari N — University of Pittsburgh at Pittsburgh
- Study coordinator: Nejak-Bowen, Kari N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.